The U.S. Food and Drug Administration (FDA) plans to hold a meeting in July to discuss whether certain pharmacies should be allowed to produce specific peptides. Peptides, which are short chains of amino acids, have become popular among wellness influencers and athletes, despite many not being thoroughly tested for safety or effectiveness. These substances are often sourced from compounding pharmacies or unregulated providers abroad. The FDA’s Pharmacy Compounding Advisory Committee will consider if licensed pharmacies can manufacture at least seven peptides, including those used for inflammation, wound healing, and cognitive issues. The panel will provide recommendations but not make an official decision. This discussion is significant as it addresses the growing gray market for peptides and aims to shift demand away from unregulated sources.
QUESTION: How might the regulation of peptides by the FDA impact the way young people view and use wellness products?
The Trump administration is looking to experts to weigh in on peptides
